Literature DB >> 24525017

Protection to homologous and heterologous challenge in pigs immunized with vaccine against foot-and-mouth disease type O caused an epidemic in East Asia during 2010/2011.

Jeong-Nam Park1, Seo-Yong Lee1, Jia-Qi Chu2, Yeo-Joo Lee1, Rae-Hyung Kim1, Kwang-Nyeong Lee1, Su-Mi Kim1, Dong-Seob Tark1, Byounghan Kim1, Jong-Hyeon Park3.   

Abstract

Foot-and-mouth disease (FMD) is a highly contagious infectious disease, and the use of vaccines is known to be effective for its prevention. In 2010/2011, there was an epidemic of the South East Asia (SEA) topotype in East Asian countries. We adapted the SEA topotype virus isolated in November 2010 in Korea in cells to analyze the characteristics of the virus and evaluate its possibility as a vaccine. After cell culture adaptation, the FMD virus particle 146S was purified to develop an inactivated oil vaccine for SEA or other topotypes. To measure its immunogenicity, pigs were inoculated with the experimental vaccine at different concentrations of the antigen. The results indicated that the groups immunized with at least 7.5 μg antigen were protected from homologous challenge. The immunized pigs were also protected against heterologous virus (ME-SA topotype) challenge. The genetic variations between the two field isolates and the adapted vaccine strains were identified in six amino acids by complete genome sequencing.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Foot-and-mouth disease; Heterologous challenge; Homologous challenge; Inactivated vaccine; O–SEA topotype

Mesh:

Substances:

Year:  2014        PMID: 24525017     DOI: 10.1016/j.vaccine.2014.01.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Supplementation of dietary germanium biotite enhances induction of the immune responses by foot-and-mouth disease vaccine in cattle.

Authors:  Myunghwan Jung; Min-Kyoung Shin; Seung-Bin Cha; Seung Won Shin; Anna Yoo; Won-Jung Lee; Hong-Tae Park; Jong-Hyeon Park; Byounghan Kim; Yeon-Kwon Jung; Han Sang Yoo
Journal:  BMC Vet Res       Date:  2014-08-12       Impact factor: 2.741

2.  Mincle and STING-Stimulating Adjuvants Elicit Robust Cellular Immunity and Drive Long-Lasting Memory Responses in a Foot-and-Mouth Disease Vaccine.

Authors:  Min Ja Lee; Hyundong Jo; Sung Ho Shin; Su-Mi Kim; Byounghan Kim; Hang Sub Shim; Jong-Hyeon Park
Journal:  Front Immunol       Date:  2019-10-29       Impact factor: 7.561

3.  Evaluation of novel inactivated vaccines for the SAT 1, SAT 2 and SAT 3 serotypes of foot-and-mouth disease in pigs.

Authors:  Hye-Eun Jo; Su-Hwa You; Joo-Hyung Choi; Mi-Kyeong Ko; Sung Ho Shin; Jisoo Song; Hyundong Jo; Min Ja Lee; Su-Mi Kim; Byounghan Kim; Jong-Hyeon Park
Journal:  Virol J       Date:  2019-12-16       Impact factor: 4.099

4.  Scale-Up Production of Type O and A Foot-and-Mouth Disease Bivalent Vaccine and Its Protective Efficacy in Pigs.

Authors:  Sang-Hyun Park; Seo-Yong Lee; Jae-Seok Kim; Ah-Young Kim; Sun-Young Park; Ji-Hye Lee; Mijung Lee; Hyejin Kim; Sim-In Lee; Na-Young Kang; Jung-Won Park; Su-Mi Kim; Jong-Hyeon Park; Young-Joon Ko
Journal:  Vaccines (Basel)       Date:  2021-06-02

Review 5.  Challenges of Generating and Maintaining Protective Vaccine-Induced Immune Responses for Foot-and-Mouth Disease Virus in Pigs.

Authors:  Nicholas A Lyons; Young S Lyoo; Donald P King; David J Paton
Journal:  Front Vet Sci       Date:  2016-11-30

6.  Immune responses in pigs and cattle vaccinated with half-volume foot-and-mouth disease vaccine.

Authors:  Min-Eun Park; Su-Hwa You; Seo-Yong Lee; Kwang-Nyeong Lee; Mi-Kyeong Ko; Joo-Hyung Choi; Byounghan Kim; Jong-Soo Lee; Jong-Hyeon Park
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

7.  Selection of vaccine strains for serotype O foot-and-mouth disease viruses (2007-2012) circulating in Southeast Asia, East Asia and Far East.

Authors:  Mana Mahapatra; Sasmita Upadhyaya; Sharie Aviso; Aravindh Babu; Geoff Hutchings; Satya Parida
Journal:  Vaccine       Date:  2017-11-20       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.